^
Association details:
| Biomarker: | ROS1 positive + MET amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
1103/16-MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
Published date:
03/09/2022
Excerpt:
To determine prevalence of MET amplification in entrectinib-resistant ROS1+ NSCLC...1 patient had no detectible CNA at study baseline but MET CNA gain by day 166 of entrectinib therapy and the other had detectable MET CNA gains both at baseline and at progression only 28 days later. Both received 3 lines of therapy prior to entrectinib, none of which targeted ROS1 or MET....In conclusion, we demonstrated MET gene amplification as a potential mechanism of resistance to ROS1 TKI entrectinib.
